Allogeneic bone marrow transplantation in myelofibrosis (program ID: 229063)
Charite University Hospital Berlin
Ulrich KeilholzSpecialized in: oncology, hematology
Charité Comprehensive Cancer Center
- Initial presentation in the clinic
- case history collection
- general clinical examination
- laboratory tests:
- complete blood count
- biochemical analysis of blood
- TSH-basal, fT3, fT4
- differential blood count
- inflammation indicators (CRP, ESR)
- indicators of blood coagulation
- CT/MRI scans of the whole body
- needle biopsy of the bone marrow
- biopsy and histological examination of CSF
- examination by experts of:
- registration in the European bone marrow donor base
- conducting high-dose chemotherapy
- allogeneic bone marrow transplantation from
- the cost of blood products
- isolation by neutropenic precautions
- symptomatic treatment
- control examinations
- the cost of essential medicines and materials
- nursing services
- full hospital accommodation
- explanation of future recommendations
How program is carried out
During the first visit, the doctor will conduct a clinical examination and go through the results of the available diagnostic tests. After that, you will undergo the necessary additional examination, such as the assessment of liver and kidney function, ultrasound scan, CT scan and MRI.
Also, the doctor will conduct a bone marrow biopsy followed by cytological examination of the harvested material. This will help him to determine the histological features of your bone marrow (in particular, identify HLA system antigens) and select a suitable donor. The donor can be a family member or a person from the bone marrow registry. In the second case, the donor material is stored in a bone marrow bank.
Before the procedure, you will receive chemotherapy, if necessary in combination with radiation therapy. The course of chemo- or chemoradiation therapy lasts from 2 to 8 days.
The bone marrow transplant procedure is an intravenous infusion, i.e. the healthy bone marrow will be injected through a catheter, intravenously. You will stay in your room during the procedure. A bone marrow transplant is completely painless and does not require anesthesia.
During the period of healthy bone marrow engraftment, you will stay in a sterile ward. This is a necessary precaution because during this time your immune system is very weak and cannot withstand environmental pathogens. The risk of bleeding is also quite high, so you will be advised to avoid mechanical damage.
A relative or other close person may stay in the ward with you. You will not be allowed to go outside the department and leave your ward often. The rehabilitation period can last from 1 to 2 months.
When your complete blood count returns to normal, your doctor will schedule your discharge from the department. You will receive information about the rules that you will need to follow at home, the frequency and type of control examinations, and subsequent treatment measures. You will also receive a detailed medical report, which will reflect the entire course of treatment.
- Medical records
- Bone marrow biopsy results (if available)
You may also book
About the department
197 Booking Health patients have already received treatment in the Comprehensive Cancer Center at the Charite University Hospital Berlin.
96% of patients recommend this hospital and department.
You can read reviews about the quality of the Booking Health service here.
Charité Comprehensive Cancer Center at the Charite University Hospital Berlin offers patients the full range of classical and innovative examinations, treatment of malignant diseases of all organs and anatomical structures of the human body. The spectrum is complemented by follow-up medical care, rehabilitation, modern schemes for the prevention and early detection of malignant diseases. An important component of the therapeutic process in the center is psycho-oncological care. The centerdals with the treatment of patients of all age groups, ranging from small children to elderly patients. The center is headed by Prof. Dr. med. Ulrich Keilholz.
The center takes part in many leading clinical researches on the optimization of existing and the development of innovative therapeutic techniques. It integrates the work of all departments of the hospital engaged in the treatment of various types of cancers, therefore, the specialists from all medical fields cooperate closely here.
The center specializes in the diagnostics and treatment of the following malignant diseases:
|Tumors of the brain and spinal cord|
|Bone and soft tissue tumors||Sarcomas|
|Head and neck tumors|
|Cancer of the liver and biliary tract|
|Leukemia, lymphoma, multiple myeloma|
|Lung cancer, including thymus cancer and pleural mesothelioma|
|Esophageal and stomach cancer|
|Adrenal cancer, neuroblastoma, pheochromocytoma|
|Neuroendocrine tumors with localization in the small and large intestines, pancreas, lung, stomach, cancer with unknown primary localization|
|Cancer in children and adolescents|
|Other oncological diseases|
- 2015 Appointed as Professor in Oncology (W3) and Head of the Charite Comprehensive Cancer Center.
- 2013 - 2015 Acting Director of the Charite Comprehensive Cancer Center, Berlin.
- 2008 - 2013 Deputy Director of the Charite Comprehensive Cancer Center.
- 2003 - 2015 C3 Professor in Clinical and Molecular Oncological Immunology, Charite University Hospital Berlin.
- 1998 Visiting Professor in Internal Medicine, Free University of Berlin.
- 1997 - 2013 Deputy Head, Department of Hematology, Oncology and Oncological Immunology, Charite University Hospital Berlin.
- 1993 Habilitation, Internal Medicine, Heidelberg University.
- 1993 Qualification in Hematology and Internal Oncology.
- 1990 - 1997 Senior Physician, Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg.
- 1990 Medical Specialist in Internal Medicine.
- 1986 Scientific Internship at the National Cancer Institute, Bethesda, USA, Surgery, Department of Immunotherapy.
- 1983 - 1990 Fellow, Heidelberg University, University Hospital Heidelberg.
- 1984 PhD defense, Institute of Pathophysiology and Sports Medicine, Heidelberg University.
- 1977 - 1983 Study of Medicine at the University of Mainz, Heidelberg University, University of Lexington (USA).
Activities in the Scientific Societies
- 1999 - 2006 Board Member of the Working Group on Internal Oncology.
- 2003 - 2005 Working Group on Melanoma Treatment (EORTC), Secretary (2001 - 2003), Board Member (2003 - 2005).
- 2003 - 2006 International Society for Biological Cancer Therapy (iSBTc), Vice President (2003 - 2005), President (2005 - 2006).
- 2006 - 2009 National Representative of Germany in the European Society for Medical Oncology (ESMO).
Photo of the doctor: (c) Charité – Universitätsmedizin Berlin